Product Description
The global midline market was valued at around $192 million in 2025. This is expected to increase over the forecast period at a CAGR of 3.5% to reach $245 million by 2032.
The full report suite on the global market for midlines includes the accelerated Seldinger technique (AST) and modified Seldinger technique (MST) segments. The MST midline is further categorized into power-injectable and non-power-injectable.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Global Midline Market Trends
Demographic pressures and rising inpatient volumes continue to shift vascular access practices toward midlines. An aging global population and higher hospitalization rates are increasing demand for intermediate-duration intravenous access. Patients who would previously have received PICCs, or repeated PIVC placements, are increasingly managed with midline catheters to balance safety, dwell time and procedural efficiency. This structural shift in care pathways continues to underpin long-term growth in midline utilization.
Global Midline Market Share Insights
- Becton Dickinson (BD) offers a diverse range of midline products, including the PowerGlide® line and others, holding a significant share of the power-injectable AST midline market. BD stands out as it covers all midline segments. It provides older non-power-injectable options such as Groshong® Midline Catheter and Per-Q-Cath® Midline Catheter. The PowerMidline™, PowerGlide ST™, PowerGlide® and PowerGlide Pro™ cater to various lengths and configurations for AST insertions. Unlike competitors, BD midlines lack premium features such as antimicrobial or antithrombogenic properties, leading to standard ASPs.
- Teleflex ranks second in the midline market, offering a broad portfolio of midline catheter kits, including basic and maximal barrier precaution kits. Its Arrowg+ard Blue Advance™ Midline, U.S. Food and Drug Administration (FDA)-approved in 2016, uses chlorhexidine coating for antimicrobial properties, commanding a price premium due to its unique features.
- AngioDynamics entered the midline market in 2015 with BioFlo® Midline Catheters, which are power-injectable and designed to prevent thrombus buildup. In February 2024, AngioDynamics announced the sale of its PICC and midline product portfolios to Spectrum Vascular. BioFlo® midlines are power-injectable and are designed to reduce thrombus accumulation. The company has incorporated BioFlo® technology into many of its vascular access devices, such as PICCs, ports and dialysis catheters. BioFlo® technology has experienced significant growth in many product areas in recent years. With this acquisition, Spectrum Vascular aims to strengthen its presence in the vascular access market and expand its product offerings.
Global Midline Market Segmentation Summary
- MST Midline Market – Further Segmented Into:
- Device Type: Power-Injectable and Non-Power Injectable.
- AST Midline Market
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
